memantine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
adamantane derivatives 1679 19982-08-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • memantine
  • alzantin
  • memantina
  • memantine hydrochloride
  • ebixa
  • namenda
  • maruxa
  • memantine HCl
  • nemdatine
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
  • Molecular weight: 179.31
  • Formula: C12H21N
  • CLOGP: 3.03
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -3.60
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.32 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 48 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 30 mg/mL Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.53 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
May 15, 2002 EMA H. Lundbeck A/S
Oct. 16, 2003 FDA FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 308.35 14.81 495 20077 391839 63076611
Agitation 230.21 14.81 175 20397 59582 63408868
Confusional state 214.15 14.81 319 20253 236061 63232389
Aggression 167.93 14.81 101 20471 23397 63445053
Hallucination 160.99 14.81 137 20435 54680 63413770
Dementia 145.31 14.81 85 20487 18709 63449741
Abnormal behaviour 145.14 14.81 89 20483 21337 63447113
Body tinea 144.85 14.81 44 20528 1841 63466609
Somnolence 137.64 14.81 224 20348 178461 63289989
Inhibitory drug interaction 123.14 14.81 43 20529 2806 63465644
Infection susceptibility increased 121.56 14.81 45 20527 3476 63464974
Delirium 108.54 14.81 106 20466 50435 63418015
Myoclonus 105.14 14.81 65 20507 15803 63452647
Glucose tolerance impaired 97.49 14.81 46 20526 6531 63461919
Bradycardia 90.44 14.81 115 20457 73112 63395338
Seizure 84.55 14.81 153 20419 132481 63335969
Psychomotor hyperactivity 81.81 14.81 48 20524 10615 63457835
Purpura 76.34 14.81 47 20525 11338 63457112
Poor quality sleep 71.47 14.81 56 20516 19879 63448571
Syncope 70.50 14.81 132 20440 117253 63351197
Rheumatoid arthritis 66.30 14.81 4 20568 253815 63214635
Impaired quality of life 65.79 14.81 46 20526 13737 63454713
Hallucination, visual 64.45 14.81 52 20520 19246 63449204
Loss of consciousness 63.79 14.81 127 20445 117994 63350456
Urinary tract infection 61.52 14.81 207 20365 264477 63203973
Bone density decreased 61.10 14.81 45 20527 14567 63453883
Joint swelling 60.09 14.81 16 20556 327650 63140800
Encephalopathy 59.69 14.81 68 20504 38552 63429898
Disorientation 58.51 14.81 68 20504 39384 63429066
Arthralgia 57.55 14.81 60 20512 569650 62898800
Delusion 57.11 14.81 40 20532 11977 63456473
Sialoadenitis 56.36 14.81 21 20551 1651 63466799
Aphasia 55.97 14.81 61 20511 32939 63435511
Maternal exposure during pregnancy 55.89 14.81 4 20568 220058 63248392
Cellulitis 55.34 14.81 97 20475 81861 63386589
Hyperlipidaemia 53.52 14.81 47 20525 19524 63448926
Pain 52.05 14.81 101 20471 740527 62727923
Impaired work ability 51.91 14.81 44 20528 17431 63451019
Swelling 51.33 14.81 13 20559 275365 63193085
Infusion related reaction 51.06 14.81 9 20563 245512 63222938
Dyskinesia 50.56 14.81 57 20515 31945 63436505
Arthropathy 50.17 14.81 8 20564 234784 63233666
Dysphagia 48.72 14.81 96 20476 88489 63379961
Drug hypersensitivity 48.51 14.81 20 20552 310667 63157783
Speech disorder 47.30 14.81 62 20510 40567 63427883
Death 46.79 14.81 242 20330 374139 63094311
Amyloid related imaging abnormality-oedema/effusion 46.46 14.81 11 20561 173 63468277
Alopecia 46.19 14.81 26 20546 337510 63130940
Hyponatraemia 44.09 14.81 106 20466 111794 63356656
Gait disturbance 43.16 14.81 144 20428 183034 63285416
Product administration interrupted 43.07 14.81 24 20548 4812 63463638
Drug interaction 42.83 14.81 167 20405 228964 63239486
Systemic lupus erythematosus 42.70 14.81 8 20564 208910 63259540
Chorea 42.61 14.81 17 20555 1607 63466843
Depressed level of consciousness 42.58 14.81 74 20498 62004 63406446
Orthostatic hypotension 41.81 14.81 55 20517 36105 63432345
Cognitive disorder 41.54 14.81 69 20503 55746 63412704
Mental status changes 40.88 14.81 57 20515 39542 63428908
Skin disorder 40.67 14.81 49 20523 29458 63438992
Oral herpes 40.44 14.81 46 20526 26028 63442422
Hypernatraemia 40.10 14.81 27 20545 7582 63460868
Myocardial oedema 39.88 14.81 10 20562 202 63468248
Sinusitis 39.79 14.81 12 20560 226641 63241809
Urinary retention 39.63 14.81 49 20523 30252 63438198
Tremor 39.55 14.81 113 20459 132126 63336324
Electrocardiogram PR prolongation 39.43 14.81 13 20559 711 63467739
Drug intolerance 39.12 14.81 26 20546 308635 63159815
Dementia Alzheimer's type 38.26 14.81 14 20558 1046 63467404
Lack of spontaneous speech 36.98 14.81 9 20563 160 63468290
Intestinal pseudo-obstruction 36.49 14.81 13 20559 899 63467551
Lethargy 36.13 14.81 65 20507 55942 63412508
Product adhesion issue 35.56 14.81 21 20551 4698 63463752
Altered state of consciousness 34.94 14.81 42 20530 25188 63443262
Electrocardiogram QT prolonged 34.53 14.81 66 20506 59464 63408986
Abdominal discomfort 34.39 14.81 32 20540 320853 63147597
Immune thrombocytopenia 34.30 14.81 28 20544 10528 63457922
Cerebral atrophy 34.18 14.81 21 20551 5045 63463405
Exposure during pregnancy 33.90 14.81 5 20567 155542 63312908
Incoherent 33.72 14.81 20 20552 4510 63463940
Anxiety disorder 33.10 14.81 19 20553 4031 63464419
Sedation 33.02 14.81 51 20521 38758 63429692
Pneumonia aspiration 31.67 14.81 47 20525 34493 63433957
Accidental overdose 30.97 14.81 38 20534 23271 63445179
Contraindicated product administered 30.86 14.81 16 20556 217632 63250818
Posture abnormal 30.58 14.81 15 20557 2317 63466133
Dehydration 30.48 14.81 124 20448 173230 63295220
Balance disorder 30.10 14.81 77 20495 84345 63384105
Failure to thrive 29.71 14.81 22 20550 7176 63461274
Pulmonary embolism 29.50 14.81 94 20478 116590 63351860
Hypophagia 29.33 14.81 43 20529 31216 63437234
Hypersensitivity 29.27 14.81 31 20541 292654 63175796
Treatment failure 29.17 14.81 14 20558 199029 63269421
Behaviour disorder 28.83 14.81 16 20556 3183 63465267
Immobile 28.74 14.81 20 20552 5923 63462527
Dyspnoea 28.58 14.81 114 20458 661199 62807251
Cerebral haemorrhage 28.44 14.81 42 20530 30687 63437763
Hip fracture 28.31 14.81 41 20531 29433 63439017
Cataract 28.00 14.81 59 20513 56994 63411456
Belligerence 27.35 14.81 7 20565 154 63468296
Metastatic neoplasm 26.94 14.81 17 20555 4278 63464172
Disturbance in attention 26.80 14.81 46 20526 38143 63430307
Akinesia 26.27 14.81 12 20560 1581 63466869
Emotional poverty 25.96 14.81 8 20564 351 63468099
Febrile neutropenia 25.36 14.81 4 20568 118445 63350005
Nasopharyngitis 25.34 14.81 27 20545 254230 63214220
Decreased appetite 25.13 14.81 153 20419 250899 63217551
Lower respiratory tract infection 25.11 14.81 6 20566 132301 63336149
Akathisia 25.08 14.81 22 20550 9124 63459326
Hypersomnia 24.91 14.81 30 20542 18025 63450425
Therapeutic product effect decreased 24.82 14.81 16 20556 193171 63275279
Rash 24.65 14.81 96 20476 560775 62907675
Asthenia 24.61 14.81 210 20362 383394 63085056
Discomfort 24.18 14.81 12 20560 167362 63301088
Restlessness 24.07 14.81 38 20534 29415 63439035
Pyrexia 23.69 14.81 76 20496 470402 62998048
Memory impairment 23.67 14.81 81 20491 104177 63364273
Inappropriate antidiuretic hormone secretion 23.50 14.81 27 20545 15435 63453015
Head injury 23.30 14.81 36 20536 27360 63441090
Stomatitis 23.18 14.81 8 20564 138717 63329733
Dizziness 22.84 14.81 226 20346 429699 63038751
Pain in extremity 22.49 14.81 46 20526 331440 63137010
Hepatic enzyme increased 21.87 14.81 20 20552 202308 63266142
Eye haematoma 21.86 14.81 5 20567 67 63468383
Diet refusal 21.68 14.81 8 20564 612 63467838
Parkinsonism 20.73 14.81 21 20551 10418 63458032
Irritability 20.71 14.81 37 20535 31657 63436793
Gait inability 20.66 14.81 50 20522 52909 63415541
Abdominal pain 20.52 14.81 40 20532 293416 63175034
Blood creatine phosphokinase increased 20.50 14.81 36 20536 30394 63438056
Drug-device interaction 20.43 14.81 5 20567 91 63468359
Device pacing issue 20.38 14.81 5 20567 92 63468358
Crying 20.31 14.81 31 20541 23312 63445138
Dermatitis atopic 20.12 14.81 20 20552 9704 63458746
Metastases to central nervous system 20.11 14.81 23 20549 13082 63455368
Psoriatic arthropathy 19.80 14.81 3 20569 91517 63376933
Wrong patient received product 19.78 14.81 11 20561 2196 63466254
Stupor 19.77 14.81 14 20558 4261 63464189
Schizophrenia 19.73 14.81 20 20552 9932 63458518
Parkinson's disease 19.53 14.81 9 20563 1210 63467240
Epilepsy 19.52 14.81 33 20539 27032 63441418
Anger 19.35 14.81 22 20550 12434 63456016
Floppy iris syndrome 19.24 14.81 5 20567 117 63468333
Wound 19.03 14.81 15 20557 163248 63305202
Vitamin D deficiency 19.03 14.81 23 20549 13869 63454581
Therapeutic drug monitoring analysis not performed 18.64 14.81 9 20563 1343 63467107
Aptyalism 18.63 14.81 7 20565 563 63467887
Subdural haematoma 18.46 14.81 23 20549 14305 63454145
Angina pectoris 18.24 14.81 34 20538 30044 63438406
Extrapyramidal disorder 18.20 14.81 22 20550 13262 63455188
Infection 18.04 14.81 29 20543 229144 63239306
Anaemia neonatal 17.98 14.81 6 20566 341 63468109
Headache 17.90 14.81 126 20446 633115 62835335
Retinopathy of prematurity 17.78 14.81 6 20566 353 63468097
Eating disorder 17.61 14.81 26 20546 18990 63449460
Diabetic hyperosmolar coma 17.60 14.81 6 20566 364 63468086
Muscle rigidity 17.34 14.81 20 20552 11480 63456970
Incontinence 17.15 14.81 20 20552 11612 63456838
Oroantral fistula 16.82 14.81 5 20567 194 63468256
Non-24-hour sleep-wake disorder 16.71 14.81 3 20569 10 63468440
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 16.60 14.81 4 20568 68 63468382
Pruritus 16.41 14.81 61 20511 361392 63107058
Psoriasis 16.38 14.81 4 20568 86953 63381497
Granulocytopenia 16.27 14.81 14 20558 5658 63462792
Apathy 16.22 14.81 17 20555 8777 63459673
Insomnia 16.03 14.81 122 20450 215130 63253320
Moaning 15.96 14.81 7 20565 839 63467611
Application site rash 15.95 14.81 10 20562 2488 63465962
Neutropenia 15.90 14.81 20 20552 174985 63293465
Arthritis 15.72 14.81 9 20563 115912 63352538
Pleurothotonus 15.70 14.81 8 20564 1341 63467109
Personality change 15.66 14.81 15 20557 6958 63461492
Nausea 15.52 14.81 190 20382 854281 62614169
Unresponsive to stimuli 15.47 14.81 34 20538 33782 63434668
Decubitus ulcer 15.37 14.81 18 20554 10502 63457948
Gastrointestinal disorder 15.37 14.81 12 20560 131227 63337223
Visual impairment 15.29 14.81 61 20511 84385 63384065
Medication error 14.95 14.81 44 20528 52240 63416210

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 277.44 15.40 204 14408 51294 34891025
Confusional state 235.72 15.40 295 14317 143865 34798454
Fall 224.83 15.40 344 14268 202541 34739778
Dementia 141.91 15.40 82 14530 13666 34928653
Aggression 124.44 15.40 114 14498 38850 34903469
Abnormal behaviour 116.72 15.40 91 14521 24878 34917441
Somnolence 104.15 15.40 175 14437 110941 34831378
Agitation 91.08 15.40 116 14496 57283 34885036
Gait disturbance 83.61 15.40 137 14475 85003 34857316
Delusion 72.28 15.40 52 14560 12583 34929736
Pleurothotonus 69.26 15.40 24 14588 1181 34941138
Death 68.24 15.40 337 14275 397712 34544607
Orthostatic hypotension 67.85 15.40 68 14544 25851 34916468
Bradycardia 65.59 15.40 115 14497 75303 34867016
Delirium 65.21 15.40 86 14526 43905 34898414
Amyloid related imaging abnormality-oedema/effusion 63.93 15.40 16 14596 245 34942074
Sopor 58.35 15.40 45 14567 12091 34930228
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 53.99 15.40 13 14599 168 34942151
Memory impairment 49.81 15.40 75 14537 43243 34899076
Product administration interrupted 49.51 15.40 21 14591 1794 34940525
Eosinophilic pleural effusion 48.73 15.40 13 14599 259 34942060
Mental status changes 45.30 15.40 67 14545 38016 34904303
Pneumonia aspiration 43.21 15.40 69 14543 41834 34900485
Product adhesion issue 41.95 15.40 18 14594 1582 34940737
Prescribed underdose 40.51 15.40 32 14580 8901 34933418
Condition aggravated 39.56 15.40 172 14440 192024 34750295
Febrile neutropenia 37.76 15.40 6 14606 136843 34805476
Spur cell anaemia 37.39 15.40 8 14604 58 34942261
Syncope 36.47 15.40 102 14510 91349 34850970
Balance disorder 35.31 15.40 62 14550 40592 34901727
Gait inability 34.54 15.40 43 14569 20715 34921604
Asthenia 32.55 15.40 194 14418 245057 34697262
Subdural haematoma 31.91 15.40 41 14571 20380 34921939
Foaming at mouth 30.96 15.40 12 14600 812 34941507
Loss of consciousness 30.81 15.40 90 14522 82577 34859742
Bradyarrhythmia 30.69 15.40 16 14596 2175 34940144
Psychomotor hyperactivity 30.37 15.40 28 14584 9594 34932725
Hallucination, visual 29.83 15.40 37 14575 17754 34924565
Dementia with Lewy bodies 28.97 15.40 11 14601 704 34941615
Dysphagia 28.30 15.40 73 14539 62308 34880011
Depressed level of consciousness 28.13 15.40 58 14554 42783 34899536
Urinary tract infection 28.01 15.40 88 14524 83993 34858326
Cognitive disorder 27.87 15.40 46 14566 28647 34913672
Hypersomnia 27.86 15.40 30 14582 12377 34929942
Hyporesponsive to stimuli 27.52 15.40 12 14600 1096 34941223
Ataxia 26.82 15.40 31 14581 13822 34928497
Speech disorder 26.06 15.40 42 14570 25644 34916675
Dyskinesia 26.02 15.40 39 14573 22374 34919945
Mixed dementia 25.97 15.40 8 14604 270 34942049
Tremor 25.30 15.40 84 14528 82503 34859816
Sedation 25.03 15.40 37 14575 20969 34921350
Inappropriate antidiuretic hormone secretion 23.79 15.40 28 14584 12725 34929594
Urinary incontinence 23.58 15.40 34 14578 18840 34923479
Hypophagia 22.64 15.40 38 14574 23984 34918335
Medication error 22.20 15.40 39 14573 25526 34916793
Myoclonus 22.12 15.40 29 14583 14696 34927623
Nonspecific reaction 21.78 15.40 11 14601 1400 34940919
Drug hypersensitivity 21.17 15.40 4 14608 80525 34861794
Disorientation 20.69 15.40 44 14568 33144 34909175
Conduction disorder 20.21 15.40 12 14600 2098 34940221
Restlessness 19.75 15.40 37 14575 25445 34916874
Product dose omission issue 19.36 15.40 100 14512 119611 34822708
Sinus bradycardia 18.66 15.40 25 14587 12938 34929381
Seizure 18.66 15.40 90 14522 104767 34837552
Decreased appetite 18.53 15.40 126 14486 166266 34776053
Neutropenia 18.51 15.40 23 14589 156755 34785564
Hypernatraemia 18.14 15.40 20 14592 8470 34933849
Disturbance in attention 18.06 15.40 36 14576 25909 34916410
Accidental overdose 17.85 15.40 31 14581 20109 34922210
Therapeutic response unexpected 17.50 15.40 21 14591 9736 34932583
Illusion 17.48 15.40 8 14604 819 34941500
Parkinsonism 17.09 15.40 19 14593 8119 34934200
Paranoia 16.95 15.40 23 14589 12045 34930274
Dysstasia 16.76 15.40 23 14589 12172 34930147
Application site erythema 16.62 15.40 11 14601 2325 34939994
Abnormal dreams 16.45 15.40 18 14594 7560 34934759
Decreased activity 16.30 15.40 14 14598 4373 34937946
Electrocardiogram QT prolonged 15.64 15.40 45 14567 40907 34901412

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fall 437.32 13.81 696 28324 486933 79228435
Confusional state 355.92 13.81 504 28516 317493 79397875
Hallucination 300.18 13.81 249 28771 85496 79629872
Aggression 230.05 13.81 172 28848 50786 79664582
Agitation 226.12 13.81 227 28793 99488 79615880
Dementia 195.19 13.81 118 28902 24541 79690827
Somnolence 184.80 13.81 320 28700 238661 79476707
Abnormal behaviour 171.22 13.81 126 28894 36295 79679073
Bradycardia 138.20 13.81 206 28814 135351 79580017
Body tinea 136.36 13.81 43 28977 1811 79713557
Death 128.04 13.81 474 28546 566040 79149328
Myoclonus 123.97 13.81 93 28927 27567 79687801
Delirium 120.12 13.81 151 28869 84476 79630892
Infection susceptibility increased 110.55 13.81 44 28976 3677 79711691
Delusion 110.54 13.81 77 28943 20346 79695022
Psychomotor hyperactivity 99.41 13.81 67 28953 16782 79698586
Gait disturbance 96.55 13.81 225 28795 207281 79508087
Inhibitory drug interaction 96.36 13.81 42 28978 4411 79710957
Amyloid related imaging abnormality-oedema/effusion 92.10 13.81 23 28997 404 79714964
Orthostatic hypotension 87.40 13.81 105 28915 56059 79659309
Pleurothotonus 86.23 13.81 33 28987 2483 79712885
Loss of consciousness 84.64 13.81 188 28832 167755 79547613
Product administration interrupted 81.85 13.81 36 28984 3863 79711505
Glucose tolerance impaired 80.72 13.81 45 28975 8039 79707329
Syncope 78.49 13.81 190 28830 179259 79536109
Hallucination, visual 76.83 13.81 76 28944 32653 79682715
Pneumonia aspiration 74.31 13.81 106 28914 66861 79648507
Mental status changes 71.40 13.81 104 28916 66855 79648513
Seizure 70.17 13.81 188 28832 188646 79526722
Arthralgia 68.99 13.81 64 28956 571739 79143629
Poor quality sleep 61.35 13.81 57 28963 22665 79692703
Drug hypersensitivity 60.37 13.81 17 29003 298899 79416469
Rheumatoid arthritis 60.18 13.81 4 29016 208466 79506902
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 58.44 13.81 14 29006 205 79715163
Bone density decreased 57.85 13.81 44 28976 13303 79702065
Disorientation 57.70 13.81 91 28929 62685 79652683
Speech disorder 57.22 13.81 84 28936 54361 79661007
Joint swelling 57.22 13.81 17 29003 288629 79426739
Depressed level of consciousness 56.52 13.81 115 28905 96537 79618831
Dyskinesia 55.86 13.81 75 28945 44698 79670670
Impaired quality of life 54.93 13.81 44 28976 14342 79701026
Asthenia 54.40 13.81 345 28675 511344 79204024
Tremor 54.02 13.81 160 28860 169923 79545445
Sialoadenitis 53.72 13.81 22 28998 1979 79713389
Urinary tract infection 53.04 13.81 219 28801 274293 79441075
Febrile neutropenia 52.87 13.81 10 29010 230989 79484379
Purpura 52.75 13.81 49 28971 19478 79695890
Eosinophilic pleural effusion 52.37 13.81 14 29006 325 79715043
Dysphagia 51.96 13.81 128 28892 122008 79593360
Cognitive disorder 51.76 13.81 92 28928 69834 79645534
Infusion related reaction 50.54 13.81 11 29009 230226 79485142
Inappropriate antidiuretic hormone secretion 49.02 13.81 54 28966 26259 79689109
Sopor 48.56 13.81 60 28960 32950 79682418
Electrocardiogram QT prolonged 47.55 13.81 103 28917 90283 79625085
Failure to thrive 46.88 13.81 37 28983 11807 79703561
Balance disorder 46.79 13.81 108 28912 98749 79616619
Hypophagia 44.81 13.81 68 28952 45299 79670069
Aphasia 44.69 13.81 69 28951 46663 79668705
Sedation 43.29 13.81 72 28948 51823 79663545
Disturbance in attention 43.07 13.81 71 28949 50730 79664638
Hyperlipidaemia 42.58 13.81 50 28970 26043 79689325
Arthropathy 41.97 13.81 7 29013 177104 79538264
Encephalopathy 41.55 13.81 82 28938 67315 79648053
Altered state of consciousness 40.92 13.81 64 28956 43758 79671610
Swelling 40.74 13.81 14 29006 216697 79498671
Hypersomnia 40.64 13.81 46 28974 23040 79692328
Posture abnormal 39.91 13.81 22 28998 3844 79711524
Dementia with Lewy bodies 39.75 13.81 14 29006 832 79714536
Subdural haematoma 39.73 13.81 53 28967 31381 79683987
Impaired work ability 39.48 13.81 42 28978 19639 79695729
Accidental overdose 37.23 13.81 58 28962 39523 79675845
Incoherent 37.01 13.81 27 28993 7665 79707703
Gait inability 36.70 13.81 72 28948 58845 79656523
Pain 36.23 13.81 133 28887 703669 79011699
Maternal exposure during pregnancy 35.65 13.81 4 29016 136534 79578834
Skin disorder 35.12 13.81 52 28968 33891 79681477
Hip fracture 34.56 13.81 49 28971 30712 79684656
Electrocardiogram PR prolongation 34.47 13.81 15 29005 1568 79713800
Memory impairment 34.40 13.81 104 28916 111630 79603738
Spur cell anaemia 33.66 13.81 8 29012 113 79715255
Drug interaction 33.53 13.81 262 28758 414921 79300447
Lack of spontaneous speech 33.03 13.81 9 29011 225 79715143
Hypernatraemia 32.88 13.81 33 28987 14418 79700950
Medication error 32.48 13.81 75 28945 68567 79646801
Lethargy 32.26 13.81 83 28937 81209 79634159
Decreased appetite 32.15 13.81 224 28796 342194 79373174
Sinusitis 31.32 13.81 16 29004 195485 79519883
Oral herpes 31.24 13.81 44 28976 27410 79687958
Dehydration 31.20 13.81 175 28845 248012 79467356
Bradyarrhythmia 30.64 13.81 19 29001 4127 79711241
Cerebral haemorrhage 30.64 13.81 66 28954 57607 79657761
Restlessness 30.40 13.81 58 28962 46434 79668934
Abdominal pain 30.29 13.81 60 28960 389509 79325859
Rash 29.93 13.81 109 28911 578249 79137119
Ataxia 29.79 13.81 41 28979 24998 79690370
Sinus bradycardia 29.53 13.81 41 28979 25206 79690162
Dyspnoea 29.50 13.81 187 28833 856838 78858530
Cerebral atrophy 29.35 13.81 24 28996 8051 79707317
Hyponatraemia 28.32 13.81 134 28886 177714 79537654
Neutropenia 28.26 13.81 38 28982 287672 79427696
Systemic lupus erythematosus 28.23 13.81 5 29015 121144 79594224
Contraindicated product administered 28.21 13.81 11 29009 157527 79557841
Neuroleptic malignant syndrome 28.20 13.81 42 28978 27517 79687851
Behaviour disorder 27.77 13.81 21 28999 6292 79709076
Head injury 27.43 13.81 49 28971 37320 79678048
Parkinsonism 27.43 13.81 32 28988 16552 79698816
Drug intolerance 26.85 13.81 34 28986 264085 79451283
Mixed dementia 26.71 13.81 8 29012 283 79715085
Stomatitis 26.69 13.81 10 29010 146747 79568621
Nasopharyngitis 26.52 13.81 32 28988 253849 79461519
Foaming at mouth 25.86 13.81 13 29007 1884 79713484
Urinary retention 25.83 13.81 61 28959 56569 79658799
Urinary incontinence 25.48 13.81 50 28970 40859 79674509
Hypersensitivity 25.39 13.81 35 28985 262204 79453164
Generalised tonic-clonic seizure 25.36 13.81 52 28968 43858 79671510
Mania 24.96 13.81 32 28988 18228 79697140
Crying 24.85 13.81 36 28984 23007 79692361
Prescribed underdose 24.68 13.81 41 28979 29473 79685895
Hyporesponsive to stimuli 24.68 13.81 13 29007 2075 79713293
Incontinence 24.55 13.81 28 28992 14136 79701232
International normalised ratio increased 24.35 13.81 77 28943 84644 79630724
Alopecia 24.34 13.81 29 28991 231326 79484042
Product adhesion issue 24.16 13.81 14 29006 2690 79712678
Pruritus 24.13 13.81 69 28951 394579 79320789
Akinesia 24.03 13.81 15 29005 3297 79712071
Dizziness 23.68 13.81 294 28726 526147 79189221
Anger 23.34 13.81 30 28990 17132 79698236
Irritability 22.91 13.81 48 28972 41096 79674272
Therapeutic product effect decreased 22.62 13.81 16 29004 163847 79551521
Cataract 22.18 13.81 61 28959 62059 79653309
Intestinal pseudo-obstruction 21.97 13.81 13 29007 2596 79712772
Exposure during pregnancy 21.84 13.81 5 29015 101127 79614241
Condition aggravated 21.73 13.81 278 28742 500846 79214522
Cerebral infarction 21.71 13.81 50 28970 45626 79669742
Pain in extremity 21.37 13.81 65 28955 364473 79350895
Muscle rigidity 21.35 13.81 31 28989 19851 79695517
Emotional poverty 21.28 13.81 9 29011 878 79714490
Akathisia 20.96 13.81 25 28995 13234 79702134
Arthritis 20.60 13.81 8 29012 114872 79600496
Paranoia 20.43 13.81 30 28990 19402 79695966
Eating disorder 20.40 13.81 31 28989 20666 79694702
Pyrexia 20.39 13.81 154 28866 678555 79036813
Chorea 20.24 13.81 12 29008 2405 79712963
Lower respiratory tract infection 20.07 13.81 11 29009 129209 79586159
Immobile 19.81 13.81 18 29002 6955 79708413
Headache 19.80 13.81 148 28872 653624 79061744
Extrapyramidal disorder 19.63 13.81 32 28988 22647 79692721
Intentional product use issue 19.52 13.81 16 29004 152096 79563272
Immune thrombocytopenia 19.47 13.81 28 28992 17777 79697591
Haemorrhagic stroke 19.42 13.81 22 28998 11024 79704344
Aptyalism 19.15 13.81 8 29012 757 79714611
Infection 18.97 13.81 37 28983 241675 79473693
Tardive dyskinesia 18.49 13.81 21 28999 10550 79704818
Hepatic enzyme increased 18.04 13.81 24 28996 182586 79532782
Discomfort 17.68 13.81 12 29008 125605 79589763
Asthma 17.60 13.81 14 29006 135081 79580287
Epilepsy 17.54 13.81 43 28977 40817 79674551
Dysstasia 17.39 13.81 34 28986 27712 79687656
Freezing phenomenon 17.34 13.81 10 29010 1904 79713464
Unresponsive to stimuli 17.23 13.81 52 28968 55736 79659632
Cellulitis 17.22 13.81 82 28938 108978 79606390
Suicidal ideation 17.21 13.81 64 28956 76276 79639092
Eye haematoma 17.08 13.81 5 29015 163 79715205
Marasmus 16.88 13.81 8 29012 1020 79714348
Metastases to central nervous system 16.81 13.81 25 28995 16350 79699018
Electrocardiogram J wave 16.61 13.81 4 29016 60 79715308
Cerebrovascular accident 16.60 13.81 105 28915 155187 79560181
Apathy 16.58 13.81 22 28998 12955 79702413
Conduction disorder 16.57 13.81 12 29008 3367 79712001
Decreased activity 16.46 13.81 18 29002 8676 79706692
Nasal congestion 16.11 13.81 4 29016 76548 79638820
Helicobacter infection 15.97 13.81 3 29017 69701 79645667
Abdominal discomfort 15.93 13.81 43 28977 250684 79464684
Cough 15.89 13.81 74 28946 366715 79348653
Impaired healing 15.89 13.81 6 29014 87649 79627719
Serotonin syndrome 15.86 13.81 44 28976 44983 79670385
Hyperglycaemic hyperosmolar nonketotic syndrome 15.63 13.81 10 29010 2293 79713075
Granulocytopenia 15.57 13.81 20 29000 11411 79703957
Illusion 15.52 13.81 9 29011 1732 79713636
Fluid intake reduced 15.50 13.81 15 29005 6273 79709095
Neuropsychological test abnormal 15.39 13.81 3 29017 15 79715353
Atrioventricular block 15.23 13.81 22 28998 14019 79701349
Drowning 15.18 13.81 7 29013 838 79714530
Insomnia 15.18 13.81 146 28874 245024 79470344
Drug-device interaction 15.17 13.81 4 29016 88 79715280
Completed suicide 14.98 13.81 43 28977 245724 79469644
Diet refusal 14.98 13.81 7 29013 864 79714504
Urticaria 14.83 13.81 28 28992 185173 79530195
Decubitus ulcer 14.76 13.81 23 28997 15664 79699704
Normal pressure hydrocephalus 14.68 13.81 6 29014 537 79714831
Therapeutic drug monitoring analysis not performed 14.63 13.81 9 29011 1927 79713441
Neuropathy peripheral 14.55 13.81 18 29002 141287 79574081
Neuropsychiatric symptoms 14.46 13.81 8 29012 1407 79713961
Contusion 14.33 13.81 98 28922 148678 79566690
Lower gastrointestinal haemorrhage 14.29 13.81 23 28997 16102 79699266
Executive dysfunction 14.22 13.81 5 29015 296 79715072
Belligerence 14.01 13.81 5 29015 309 79715059
Dementia Alzheimer's type 13.94 13.81 7 29013 1012 79714356
Application site rash 13.84 13.81 9 29011 2123 79713245

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06DA52 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA53 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DX01 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000020015 NMDA Receptor Antagonists
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175745 N-methyl-D-aspartate Receptor Antagonist
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:60643 N-methyl-D-aspartate receptor antagonists
CHEBI has role CHEBI:63726 neuroprotective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderate to Severe Alzheimer's Type Dementia indication
Acute nephropathy contraindication 58574008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
14MG NAMENDA XR ABBVIE N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
21MG NAMENDA XR ABBVIE N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
28MG NAMENDA XR ABBVIE N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
7MG NAMENDA XR ABBVIE N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ABBVIE N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ABBVIE N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate receptor ionotropic, NMDA 3A Ion channel NEGATIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Glutamate receptor ionotropic, NMDA 1 Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.02 CHEMBL CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2B Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.26 CHEMBL CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 9.02 CHEMBL CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
Acetylcholinesterase Enzyme IC50 8.31 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C Ion channel Ki 6.15 CHEMBL

External reference:

IDSource
4021409 VUID
N0000148824 NUI
D04905 KEGG_DRUG
41100-52-1 SECONDARY_CAS_RN
4021409 VANDF
C0025242 UMLSCUI
CHEBI:64312 CHEBI
377 PDB_CHEM_ID
CHEMBL1699 ChEMBL_ID
CHEMBL807 ChEMBL_ID
DB01043 DRUGBANK_ID
D008559 MESH_DESCRIPTOR_UI
4054 PUBCHEM_CID
3952 INN_ID
4253 IUPHAR_LIGAND_ID
W8O17SJF3T UNII
236685 RXNORM
169783 MMSL
17635 MMSL
203022 MMSL
47628 MMSL
d04899 MMSL
006597 NDDF
006598 NDDF
406457005 SNOMEDCT_US
406458000 SNOMEDCT_US
426610008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0850 SOLUTION 10 mg ORAL ANDA 32 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0850 SOLUTION 10 mg ORAL ANDA 32 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 7 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 7 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 14 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 14 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 21 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 21 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 28 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 28 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3205 TABLET 5 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3205 TABLET 5 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3210 TABLET 10 mg ORAL NDA 31 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3210 TABLET 10 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3407 CAPSULE, EXTENDED RELEASE 7 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3407 CAPSULE, EXTENDED RELEASE 7 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3414 CAPSULE, EXTENDED RELEASE 14 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3414 CAPSULE, EXTENDED RELEASE 14 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3421 CAPSULE, EXTENDED RELEASE 21 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3421 CAPSULE, EXTENDED RELEASE 21 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3428 CAPSULE, EXTENDED RELEASE 28 mg ORAL NDA 31 sections
NamendaXR HUMAN PRESCRIPTION DRUG LABEL 1 0456-3428 CAPSULE, EXTENDED RELEASE 28 mg ORAL NDA 31 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1221 TABLET 5 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1221 TABLET 5 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1222 TABLET 10 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1222 TABLET 10 mg ORAL ANDA 27 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1943 SOLUTION 2 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1943 SOLUTION 2 mg ORAL ANDA 28 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1943 SOLUTION 2 mg ORAL ANDA 28 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3870 TABLET 5 mg ORAL NDA 29 sections